Evidence map›Paper›PMID 41920205›Full record

ArticleClinical and experimental medicine2026

S100A8-associated inflammatory microenvironment is related to its cell-of-origin and potentiates BRAF inhibitor resistance in papillary craniopharyngioma.

Chuan Zhao, Yi Lin, Huadong Chen, Hongxing Liu, Wenxin Hu, Xingfu Wang, Jintao Chen, Ning Luo, Xueling Qi, Song Han and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chuan Zhao *Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Yi Lin *Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Huadong Chen *Department of Bioinformatics, School of Medical Technology and Engineering, Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, No. 1 Xuefu North Road, Fujian, 350122, China.
Hongxing LiuDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Wenxin HuDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Xingfu WangDepartment of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350000, China.
Jintao ChenDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Ning LuoDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Xueling QiDepartment of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Song HanDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Xiaonan LiDepartment of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA.
Xianlong WangDepartment of Bioinformatics, School of Medical Technology and Engineering, Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, No. 1 Xuefu North Road, Fujian, 350122, China. wang.xianlong@139.com.
Zhixiong LinDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China. linzx@ccmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Papillary craniopharyngioma (PCP) is a BRAF mutant inflammation-related tumor that exhibits resistance to targeted therapies. This study aimed to discover mechanisms critical for PCP therapy resistance and identify new therapy target for PCP cells resistant to BRAF V600E inhibition. The microenvironment of PCP was examined using various molecular techniques, including whole-exon sequencing, transcriptome analysis, methylation profiling, and spatial data analysis. Molecular biomarkers, immunohistochemistry (IHC), and multiplex immunofluorescence (mIF) were utilized to explore the relationship between the highly inflammatory microenvironment and tumor origin-related tissue properties (TORTP). Our findings revealed that drug-resistant PCP exhibited high expression of S100A8, a biomarker associated with immune cell activation and inflammation. Crucially, this S100A8-high inflammatory signature was not exclusive to BRAF-mutant PCP. Compared to pituitary tissue, PCP displayed elevated levels of inflammatory markers, particularly S100A8. Spatial analysis within PCPs demonstrated a higher proportion of CK+/S100A8+ cells in the basal layer and S100A8+ cells in the stroma compared to RCC (Rathke’s cleft cyst). The highly S100A8-associated inflammatory microenvironment in PCP was closely linked to leukemia inhibitory factor (LIF). These factors potentiate resistance to BRAF inhibition in papillary craniopharyngioma. The distinct inflammatory microenvironment characterized by high expression of S100A8 is intrinsically linked to TORTP. Combination treatments targeting both the mutated aspects and TORTP-related factors hold significant potential to improve treatment outcomes.

Indexed as

Calgranulin ACraniopharyngiomaDrug Resistance, NeoplasmPituitary NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTumor MicroenvironmentHumansInflammationBRAF protein, humanCalgranulin AProtein Kinase InhibitorsProto-Oncogene Proteins B-rafS100A8 protein, humanDrug resistenceMicroenvironmentPapillary craniopharyngiomaS100A8

Identifiers

PMID41920205
PMCPMC13046625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.